Clazosentan
Clazosentan[edit | edit source]
Clazosentan is a selective endothelin receptor antagonist that is primarily used in the management of cerebral vasospasm following subarachnoid hemorrhage. It is a small molecule drug that specifically targets the endothelin A receptor, which plays a crucial role in the pathophysiology of vasospasm.
Mechanism of Action[edit | edit source]
Clazosentan works by blocking the action of endothelin-1, a potent vasoconstrictor peptide that binds to endothelin receptors on vascular smooth muscle cells. By inhibiting the endothelin A receptor, clazosentan prevents the vasoconstrictive effects of endothelin-1, thereby reducing the incidence and severity of cerebral vasospasm.
Clinical Use[edit | edit source]
Clazosentan is primarily indicated for patients who have experienced a subarachnoid hemorrhage, a condition where bleeding occurs in the space between the brain and the surrounding membrane. This bleeding can lead to cerebral vasospasm, which is a significant cause of morbidity and mortality in these patients. By mitigating vasospasm, clazosentan helps to improve cerebral blood flow and reduce the risk of ischemic stroke.
Pharmacokinetics[edit | edit source]
Clazosentan is administered intravenously, allowing for rapid onset of action. It is metabolized in the liver and excreted primarily through the kidneys. The pharmacokinetic profile of clazosentan supports its use in acute settings where rapid intervention is necessary.
Side Effects[edit | edit source]
Common side effects of clazosentan include hypotension, headache, and nausea. Due to its vasodilatory effects, monitoring of blood pressure is essential during treatment. Other potential adverse effects include edema and anemia.
Research and Development[edit | edit source]
Clazosentan has been the subject of several clinical trials aimed at evaluating its efficacy and safety in preventing cerebral vasospasm. These studies have demonstrated its potential benefits in improving outcomes for patients with subarachnoid hemorrhage, although further research is ongoing to optimize dosing and administration protocols.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
